Studies suggest Zepbound can help people lose weight with diet and exercise.
The drug's active ingredient is called tirzepatide. As a diabetes drug, it is sold under the brand name Mounjaro, which is manufactured by pharmaceutical company Eli Lilly and Co.
The drug is similar to semaglutide, the active ingredient in the medications Ozempic and Wegovy -- both made by Novo Nordisk -- but works slightly differently because it targets two hormones involved in blood sugar control rather than just one.found that tirzepatide helped some people with obesity or overweight lose about a quarter of their body weight -- when paired with an extensive diet and exercise program.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
FDA approves Eli Lilly’s Zepbound, a weight loss drug similar to Ozempic and WegovyBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Consulte Mais informação »
FDA approves new obesity drug from Eli Lilly named ZepboundThe decision by the Food and Drug Administration is expected to add to the demand for a new class of drugs transforming how patients battle obesity.
Consulte Mais informação »
Zepbound: FDA approves new version of diabetes drug Mounjaro for weight lossThe U.S. Food and Drug Administration on Wednesday approved a new version of the type 2 diabetes drug tirzepatide for use in chronic weight management, officials said.
Consulte Mais informação »
Eli Lilly's Obesity Drug Gets FDA ApprovalThe drug will be marketed as an obesity treatment under the name Zepbound.
Consulte Mais informação »
Eli Lilly’s Mounjaro Approved for Weight Loss in the U.S.The drug, which will be sold as Zepbound as an anti-obesity treatment, had previously been cleared by the FDA for the treatment of Type 2 diabetes
Consulte Mais informação »